Ligand id: 8473

Name: AZD5438

Structure and Physico-chemical Properties

2D Structure
Calculated Physico-chemical Properties
Hydrogen bond acceptors 7
Hydrogen bond donors 1
Rotatable bonds 5
Topological polar surface area 98.15
Molecular weight 371.14
XLogP 2.78
No. Lipinski's rules broken 0

Molecular properties generated using the CDK

No information available.
Summary of Clinical Use
AZD5438 has reached Phase I clinical trial in patients with advanced solid malignancies (NCT00088790).
Mechanism Of Action and Pharmacodynamic Effects
Dysregulation of the CDK-driven pathway is common in tumour cells [2-4], making CDKs attractive anti-cancer molecular targets [5]. Due to the functional redundancy amongst CDKs and their cyclin binding partners compounds which target a range of CDKs are likely to be more clinically effective than selective CDK inhibitors. AZD5438 causes cell cycle arrest in vitro, which translates to an antiproliferative effect in vivo [1].